Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

Completed · Phase 4 · Has a placebo group

Conditions studied: Major Depression

In brief

This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder. This study will also examine the effectiveness of an FDA approved drug called lamotrigine in decreasing the potential side effects associated with ketamine.

Key facts

Study ID

NCT00419003

Run by

Baylor College of Medicine

People needed

26

Starts

2006-12-01

Expected to finish

2008-09-01

Last updated by the study team

2019-07-31

Who can join

Age: 21 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients, 21- 70 years of age
• Subjects have a history of at least one previous episode of depression prior to the current episode (recurrent major depressive disorder) or have chronic major depressive disorder (at least two years' duration)
• Subjects have not responded to an adequate trial of one antidepressant in the current episode

You may not qualify if…

• Female subjects who are either pregnant or nursing
• Serious, unstable illnesses
• Any previous use or treatment with ketamine, or riluzole
• Past intolerance to lamotrigine, including drug rash

Where it is running

• Mount Sinai School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.